not-yet-known not-yet-known not-yet-known unknown The Efficiency of using KardiaMobile 6L in the Cardiac Electrophysiology Clinic Bahjat Z. Ghazzal MD1, Marwan M. Refaat, MD2 1 Division of Cardiology, Department of Internal Medicine, University of Massachusetts Chan Medical School , Worcester, Massachusetts, USA 2 Division of Cardiology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon Running Title: The Efficiency of KardiaMobile 6L in Clinic Words: 719 (excluding the title page and references) Keywords: Electrocardiogram, cardiac arrhythmias, cardiology, cardiovascular diseases, Utilization Time, Efficiency Funding: None Disclosures: None Corresponding Author: Marwan M. Refaat, MD, FACC, FAHA, FHRS, FASE, FESC, FACP, FRCP Tenured Professor of Medicine Tenured Professor of Biochemistry and Molecular Genetics Member, Division of Cardiology/ Section of Cardiac Electrophysiology Director, Cardiovascular Fellowship ProgramAmerican University of Beirut Faculty of Medicine and Medical Center PO Box 11-0236, Riad El-Solh 1107 2020- Beirut, Lebanon US Address: 3 Dag Hammarskjold Plaza, 8th Floor, New York, NY 10017, USA Office: +961-1-350000/+961-1-374374 Extension 5353 or Extension 5366 (Direct) Electrocardiography (ECG) is an essential diagnostic tool in cardiology, allowing for the detection and management of various cardiac conditions. Traditional 12-lead ECGs, while comprehensive, can be time-consuming and may impact clinic efficiency. This may be particularly important in outpatient cardiology clinics, where time can often be a scarce resource. A survey distributed at the 2022 ESC congress found that while most cardiologists believe that consultations should last 30 to 45 minutes, they often have only 20 minutes or less.1 Although the effects of time pressure have not been extensively studied in cardiology and cardiac electrophysiology outpatient clinics, research in primary care has linked it to increased physician stress, burnout, intent to leave the practice2 in addition to lower diagnosis rates and higher follow-up care rates3. Research has also shown that increasing system efficiency and improving patient cycle time in primary care clinics can improve patient experience and access as well as staff satisfaction.4 Thus, the introduction of KardiaMobile 6-lead ECG (Figure 1), a more portable and user-friendly device, could present an opportunity to streamline ECG collection and potentially improve clinic time utilization. The study by Gaddam et al. explores this potential by comparing room utilization times between KardiaMobile 6-lead ECG and the standard 12-lead ECG in a cardiology clinic setting. In their study, Gaddam et al. conducted a single-center, non-randomized trial involving 100 patients aged 18 to 89, excluding those with resting tremor. The participants were divided into two groups: one underwent ECG collection using KardiaMobile 6-lead ECG, and the other using the traditional 12-lead ECG. The primary outcome measured was room utilization time, with secondary outcomes including the need for additional 12-lead ECGs. The results demonstrated a significant reduction in room utilization time with KardiaMobile 6-lead ECG (7.27 minutes) compared to the 12-lead ECG (10.33 minutes, p < 0.001). Only 16% of visits in the KardiaMobile 6-lead ECG group required an additional 12-lead ECG, indicating that KardiaMobile 6-lead ECG is sufficient for most clinical needs. The primary benefit of 6-lead ECGs lies in their portability and ease of use, making them suitable for continuous monitoring and rapid assessment in both clinical and non-clinical settings. Although research on this subject is still limited, a recent prospective study of 1,015 participants found that the KardiaMobile 6-lead ECG demonstrates a high level of agreement with 12-lead ECGs for certain parameters like PR interval, QRS duration, and cardiac axis, but may be less effective for detecting conditions that require detailed precordial lead information, such as left ventricular hypertrophy or specific ischemic changes.5 Other studies have also corroborated acceptable agreement in certain ECG parameters between 6-lead and 12-lead ECG’s, however, highlighting the 12-lead ECG’s advantage in certain situations where broader and more detailed data collection is required.6,7 While this study was well-conducted, minor limitations exist. The study follows a non-randomized design, which may potentially introduce selection bias and the team members were non-blinded, which may introduce observer bias. Additionally, the relatively small sample size and single-center nature of the study may limit generalizability. It must also be noted that nearly half of the patients in each group (KardiaMobile 6-lead ECG vs. 12-lead ECG) visited the clinic for atrial fibrillation and/or atrial flutter follow-up, conditions that can be detected with just a 1-lead ECG. Finally, while the study shows a statistically significant reduction in average room utilization time by 3.07 minutes, it does not assess whether this reduction translated to meaningful improvements in tangible clinic efficiency outcomes. Despite these limitations, the study provides valuable insights into the potential benefits of integrating KardiaMobile 6-lead ECG into clinical practice. It could lead to improved clinical workflows, allowing clinicians to see more patients without compromising the quality of care. This device may also be particularly beneficial in remote or resource-limited settings where traditional 12-lead ECGs are impractical. Future research should focus on larger, randomized trials to validate these findings and explore the long-term benefits and potential limitations of KardiaMobile 6-lead ECG in diverse clinical environments. Furthermore, investigating the use of KardiaMobile 6-lead ECG in specific patient populations, such as those with complex arrhythmias or comorbidities associated with arrhythmias such as cardiomyopathies and heart failure, could provide additional insights into its clinical utility.8,9 The development of guidelines and protocols for integrating KardiaMobile 6-lead ECG into routine practice will be essential to maximize its benefits and ensure patient safety. Legend Figure 1: Kardia 6L Electrocardiogram (Mountain View, CA) References: https://doi.org/10.1016/j.jelectrocard.2021.03.008 1. Sala O, Moscatelli S. Time matters. Global assessment of quality, duration and mismatch between real practice working conditions and physician needs performing outpatients cardiological consultations. European Heart Journal . 2022;43. doi: 10.1093/eurheartj/ehac544.28352. Prasad K, Poplau S, Brown R, Yale S, Grossman E, Varkey AB, Williams E, Neprash H, Linzer M, for the Healthy Work Place I. Time Pressure During Primary Care Office Visits: a Prospective Evaluation of Data from the Healthy Work Place Study. Journal of General Internal Medicine . 2020;35:465-472. doi: 10.1007/s11606-019-05343-63. Freedman S, Golberstein E, Huang TY, Satin DJ, Smith LB. Docs with their eyes on the clock? The effect of time pressures on primary care productivity. J Health Econ . 2021;77:102442. doi: 10.1016/j.jhealeco.2021.1024424. Robinson J, Porter M, Montalvo Y, Peden CJ. Losing the wait: improving patient cycle time in primary care. BMJ Open Quality . 2020;9:e000910. doi: 10.1136/bmjoq-2019-0009105. Azram M, Ahmed N, Leese L, Brigham M, Bowes R, Wheatcroft SB, Ngantcha M, Stegemann B, Crowther G, Tayebjee MH. Clinical validation and evaluation of a novel six-lead handheld electrocardiogram recorder compared to the 12-lead electrocardiogram in unselected cardiology patients (EVALECG Cardio). European Heart Journal - Digital Health . 2021;2:643-648. doi: 10.1093/ehjdh/ztab0836. Madias JE. A Comparison of 2-Lead, 6-Lead, and 12-Lead ECGs in Patients With Changing Edematous States: Implications for the Employment of Quantitative Electrocardiography in Research and Clinical Applications. CHEST . 2003;124:2057-2063. doi: 10.1378/chest.124.6.20577. Orchard JJ, Orchard JW, Raju H, La Gerche A, Puranik R, Semsarian C. Comparison between a 6‑lead smartphone ECG and 12‑lead ECG in athletes. Journal of Electrocardiology . 2021;66:95-97. doi: 8. El Moheb M, Nicolas J, Khamis AM, Iskandarani G, Akl EA, Refaat M. Implantable Cardiac Defibrillators for patients with non-ischaemic cardiomyopathy. Cochrane Database Syst Rev Dec 2018; 12: CD012738 9. Pascual-Figal D, Wachter R, Senni M, Bao W, Noè A, Schwende H, Butylin D, Prescott MF; TRANSITION Investigators. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study. JACC Heart Fail. Aug 2020; S2213-1779(20)30336-X.